Eli Lilly and Company $LLY Shares Sold by First Trust Advisors LP

First Trust Advisors LP lessened its position in Eli Lilly and Company (NYSE:LLY) by 43.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,451 shares of the company’s stock after selling 59,620 shares during the quarter. First Trust Advisors LP’s holdings in Eli Lilly and Company were worth $58,332,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $29,000. Steph & Co. raised its position in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $31,000. Finally, Bare Financial Services Inc lifted its stake in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY is reportedly set to launch an oral obesity GLP‑1 in Q2, which would expand the market beyond injectables and support long‑term sales growth. Eli Lilly Set to Launch Oral Obesity Drug
• Positive Sentiment: The company launched an Employer Connect platform to broaden employer-sponsored access to obesity treatments, potentially increasing uptake and reducing access friction. Employer Connect Platform
• Positive Sentiment: Distribution gains: Amazon Pharmacy expanded access to LLY’s Zepbound KwikPen, improving retail availability and convenience for patients. Wider distribution should aid sales growth. Amazon Pharmacy Expands Access
• Positive Sentiment: Strategic and analyst support: LLY plans a $500M investment in South Korea’s biotech sector and J.P. Morgan reiterated a Buy rating — both signal management’s growth push and continued analyst confidence. South Korea Investment J.P. Morgan Keeps Buy Rating
• Neutral Sentiment: Macro/sector flow: crude-driven market moves and geopolitical tensions (Iran) have triggered sector rotation into aerospace and biopharma volatility; this broader rotation contributed to intraday pressure on LLY alongside other large-cap names. Sector Rotation Amid Geopolitics
• Negative Sentiment: Medicare coverage uncertainty: Eli Lilly warned some basic Medicare plans may not adhere to the $50/month out‑of‑pocket cap for weight‑loss drugs under the CMS model — this could complicate access and payer economics in the near term. Medicare Cap Warning
• Negative Sentiment: Legal risk: a U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to the older diabetes drug Actos, spotlighting potential liability and cash‑flow/legal exposure. Actos Class Action

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Daiwa Securities Group upped their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Barclays initiated coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 target price on the stock. CICC Research increased their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Finally, Scotiabank reiterated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,000.30 on Wednesday. The company’s 50-day moving average is $1,042.64 and its two-hundred day moving average is $946.71. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm has a market capitalization of $943.64 billion, a price-to-earnings ratio of 43.59, a PEG ratio of 1.17 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the firm earned $5.32 EPS. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.